CAS: 51269-82-0; 5-Chloronicotinonitrile

相似化合物

22620-27-5 113118-82-4 19230-55-8

上下游产品

CAS号2457-47-8 3,5-二氯吡啶 | CAS号544-92-3 氰化亚铜 | CAS号930-36-9 1-甲基吡唑 | CAS号67-66-3 氯仿 | CAS号616-47-7 N-甲基咪唑 | CAS号138402-36-5 3-(氨甲基)-5-氯吡啶

3-Chloro-1-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-1,4-Dihydropyridine置于2,3-二氯-5,6-二氰基-1,4-苯醌体系中,用 氯仿 作为反应溶剂,化学反应 16.0H,反应生成 3-氯-5-氰甲基吡啶
参考文献:吡啶的 C3-氰化:亲电子试剂的限制和区域选择性的决定因素
标题:吡啶的 C3-氰化:亲电子试剂的限制和区域选择性的决定因素
摘要:吡啶的 C3 选择性氰化是通过硼烷催化的吡啶硼氢化,用氰基亲电试剂取代所得二氢吡啶,最后氧化芳构化的串联过程完成的.该方法适用于吡啶类药物的后期氰化反应.
DOI:10.1002/anie.202216894

专利信息

专利号:US-9550757-B2
优先权日:2010-03-05
标题:Nuclear transport modulators and uses thereof
发明人：SHACHAM SHARON; KAUFFMAN MICHAEL; SANDANAYAKA VINCENT P; SHECHTER SHARON
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

专利号:CN-114181139-B
优先权日:2021-12-27
标题:A kind of synthesis method of 5-halogenated nicotinic acid

专利号:US-9611264-B1
优先权日:2015-09-24
标 题:N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides
发明人：BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS; VERHOEST PATRICK ROBERT; SALOMON FERRER ROMELIA DEL CARMEN
权利人:PFIZER
摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n n n n n n n n n n n n wherein the variables R 1 , R 2 and R 3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.